KineMed to Present Data on Fibrosis Biomarkers at the Keystone Fibrosis Symposium

EMERYVILLE, Calif.--()--KineMed, Inc. (www.kinemed.com) announced today that abstracts were accepted for three oral and four poster presentations highlighting its work in liver fibrosis at the Keystone Fibrosis Symposium taking place March 23–28, 2014 in Keystone, Colorado. Dr. Scott Turner, KineMed’s Executive Vice President of Research, Dr. Claire Emson, KineMed’s Director of Fibrosis Research, and Dr. Martin Decaris, postdoctoral researcher in Cellular and Molecular Kinetics at KineMed, will represent KineMed at the conference: www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1268

During the symposium workshop “Targeting Matrix Turnover: A Good or a Bad Idea?”, Dr. Decaris will give a presentation on “Proteomic Quantitation of Altered Extracellular Matrix Protein Turnover in Animal Models of Pulmonary Fibrosis”. In the following workshop titled “Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices”, Dr. Turner will present on the “Identification of a Putative Serum Protein Biomarker for Noninvasive Measurement of Fibrogenesis: Correlation with Hepatic Collagen Synthesis and Histological Score in Humans”, followed by Dr. Emson’s presentation on how “Collagen Synthesis Rate Distinguishes between Early and Late Diffuse Scleroderma Subjects”. Posters for these presentations will be on display during the poster presentations taking place on March 24th, 25th, and 26th.

In addition, KineMed will present a poster describing the work done in cooperation with Ulthera, Inc. (http://corporate.ultherapy.com/) titled “Stimulation of collagen synthesis in human skin by clinical application of micro-focused ultrasound therapy”.

About KineMed, Inc.

KineMed is a growing health technology company that has developed a proprietary biomarker platform technology with broad applications in drug development and medical diagnostics.

Using its patented technology, KineMed has developed analytic biomarker tests which measure, in a single sample, the rate of change of critical biological pathways. KineMed believes that its unique ability to measure the production and destruction of the key molecules involved in disease-modifying biological processes provides meaningful, and previously unavailable, information about both diseases and wellness, which can transform healthcare decisions. KineMed is expanding from its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests.

For more information about KineMed, please visit: www.kinemed.com

Contacts

KineMed, Inc.
Timothy L. Enns, 510-655-6525 ext. 136
Chief Investor and Media Relations Officer
Cell: 925-719-2143
tenns@kinemed.com
or
Ravi Kiron, Ph.D., MBA, 510-655-6525 ext. 105
Chief Business Officer
Cell: 650-224-3826
rkiron@kinemed.com

Contacts

KineMed, Inc.
Timothy L. Enns, 510-655-6525 ext. 136
Chief Investor and Media Relations Officer
Cell: 925-719-2143
tenns@kinemed.com
or
Ravi Kiron, Ph.D., MBA, 510-655-6525 ext. 105
Chief Business Officer
Cell: 650-224-3826
rkiron@kinemed.com